Background: Drug imprints on the surfaces of medicines could be used as accessible and economic anti-counterfeiting measures. Aims: To identify and study the structure of different types of imprints and discuss potential problems related to their structure and/or format. Methods: In total, 531 Portuguese package leaflets (PLs) were manually inspected to confirm and collect the description of the imprints. The number of letters, symbols or mixtures of both was quantified in each imprint. An electronic tool was used to evaluate the linguistic characteristics. Results: Only 7.9% of 531 PLs described imprints. Fifty-five imprints were identified: 23 (41.8%) only formed by letters and 32 (58.2%) formed by letters, numbers or symbols. It was possible to identify 171 words. Conclusion: It seems that the imprints were not systematically used as anti-counterfeiting measures. Experimental studies and the updating of pharmaceutical regulation on the suitability and specificities of these imprints are recommended.
INTRODUCTION
The graphical systems used as product identifiers (e.g. holograms or imprints on the surface of medicines) are serialisation procedures to more accurately identify the medicines, thus working as anti-counterfeiting measures.
1,2 However, there are reports from health authorities suggesting that the medicines' visual aspects may not be enough to confirm the authenticity of the medicine (e.g. laboratorial tests may be required). 2, 3 According to the pharmaceutical regulations, it is advisable to include in the package leaflets (PLs) information on the physical nature of the medicines (e.g. shape) to fully describe the aspect of the medicines. 4 Furthermore, patient safety issues, including accidental deaths associated with the improper labelling of medicines or the incorrect use of symbols and abbreviations in health documents, are widely documented in literature reports. 5, 6 Computational systems allow, among other things, the automatic evaluation of phrases/texts. For instance, these tools make it possible to automatically retrieve linguistic metrics in texts from a given language (e.g. number of orthographic wordssyllables). 7 The informatics tool FreP (Frequency Patterns of Phonological Objects in Portuguese) was specifically developed to automatically determine specific metrics in European Portuguese. 8, 9 In this context, the main aims of this research were to: (1) identify different types of imprints used on the surface of medicines, (2) evaluate the structural characteristics of these imprints (e.g. linguistic or graphic) and (3) discuss potential problems related to their structure/format.
METHODS
In total, 531 Portuguese PLs were manually inspected to check the presence of imprints. All the PLs were previously randomised from all the branded medicines mentioned in the Portuguese Prescribing Guide. 10 The medicines of the PLs with descriptions of imprints were characterised in relation to their therapeutic group, pharmaceutical presentation and administration route. There was a brief evaluation of the linguistic characteristics of the imprints, namely the number of orthographic words, segments (consonants, vowels and glides), syllables and the occurrence of abbreviations (i.e. shortened form of a word or phrases) or acronyms (formed by the initial letters of the words that compose a larger expression). 11 This evaluation was performed through the use of the informatics tool FreP. 9 It was necessary to write all the identified imprints according to the way they are orally read (e.g. the imprint '51B' was written as 'cinquenta e um bê' in Portuguese, 'fiftyone bee' in English), before they were evaluated/ processed by this automatic tool. All the retrieved results were re-evaluated by a linguist, for quality purposes. The presence of symbols, abbreviations and acronyms in the imprints was also manually checked.
RESULTS

Number and Type of PLs with Imprints
Only 42 (7.9%) of 531 PLs described imprints. The medicines mentioned in these 42 PLs were from the following: (1) routes of administration: 40 (95.2%) oral and two (4.8%) parenteral; and (2) pharmaceutical presentations: 35 (83.3%) tablets, five (11.9%) capsules and two (4.8%) injectable forms (solution and suspension). Moreover, these 42 PLs were from medicines of diverse therapeutic groups: antibacterial (five) (e.g. ciprofloxacin), central nervous system (nine) (e.g. sertraline), cardiovascular system (four) (e.g. amlodipine), blood (four) (e.g. acenocoumarol), respiratory system (one) (bromexin), digestive system (three) (e.g. esomeprazole), genitourinary (five) (e.g. finasteride), hormones (three) (e.g. cabergoline), locomotor system (four) (e.g. diclofenac), antiallergic (one) (e.g. cetirizine), electrolytes (one) (sodium) and antitumour (two) (e.g. imatinib).
Number and Type of Imprints: Some Graphic and Linguistic Features
In total, 55 different imprints were identified, with six imprints being abbreviations (e.g. SER; Table 1 ). These imprints were formed by 474 segments (nine segments per imprint on average) and 171 orthographic words with only one syllable in the majority of cases (111; 64.9%; Table 2 ). From the 55 imprints, 23 (41.8%) were formed by letters (including two cases of imprints with only one letter: 'A' and 'T') and 32 (58.2%) were formed by an association of letters, numbers or symbols (e.g. '/'). No quality problem with the retrieved results was detected by the linguistic expert.
DISCUSSION
Counterfeiting is a growing 21 st Century problem representing a global market of billions of dollars and a huge problem for the safety of millions of patients. 12 The use of medicine imprints may be a simple and economic anti-counterfeiting measure in comparison with other more advanced and expensive measures (e.g. holograms). Despite the advantages of using imprints on the surface of medicines as an anti-counterfeiting measure, it seems they were scarcely used in the sampled PLs. 1 As far we know, there is a lack of requirements on this issue that justifies: (1) a standardised use of imprints on medicine surfaces or (2) an obligatory description of the imprints in the PLs. For instance, in this study there was a wide variety of PLs containing the description of imprints (e.g. PLs of medicines from different therapeutic groups). Ideally, imprints should be described in the PLs, because their presentation favours the identification of the medicine by medicine users (e.g. using a medicine illustration in the PL section). 4 With respect to the linguistic features used in the imprints on the surface of medicines, we may note the following: (1) the imprints need to be formed by a limited number of segments/syllables, because in the majority of cases there is limited space on the surface of medicines (e.g. tablets), which also may explain the use of abbreviations as imprints; (2) imprints formed by associations between letters and symbols may be more advantageous than imprints formed only by letters, because it is likely that the imprints formed by a limited number of characters may be more easily confused with other imprints (e.g. the case of imprints formed by just one letter); and (3) the use of imprints formed by abbreviations (e.g. 'SER', which is read as just one phonological word) may be more appropriate than the use of imprints formed by acronyms (e.g. 'LTL', which is read as three phonological words, i.e. 'ele' 'tê' 'ele' in Portuguese or 'ell' 'tee' 'ell' in English), because the reading of acronyms is considered more complex/difficult. 11 Interestingly, the number of imprints with acronyms was much higher than the number of imprints with abbreviations in this study.
Our results suggest that it would be desirable to develop: (1) databases with the registration of all medicine imprints to avoid the use of the same imprint in different medicines and (2) new regulatory requirements, such as: (a) the more frequent use of imprints on the surface of medicines, (b) the non-use of similar or the same imprints on different medicines or (c) the use of the name of the medicine as an imprint in cases where enough space exists on the medicine surface. These new requirements should be based on the results of additional experimental studies, such as those on: (1) the most appropriate format for the imprints and (2) the users' satisfaction, memorisation and recall of these imprints (e.g. determining how abstract/non-abstract symbols, abbreviations or acronyms are memorised and recalled by users of medicines) such as studies using eye-tracking methodologies (which allow investigation of the areas of interest revealed by eye movements and amount of looking time) to evaluate how people process and read text/symbols (e.g. time to read a certain visual stimulus). 12 Informatics tools capable of evaluating the linguistic characteristics of written texts represent a golden opportunity for the management of large amounts of information. It seems that these tools may be useful to medicines authorities and marketing authorisation holders during the process of validation and approval of written health information.
Limitations
It was not possible to check for the presence of imprints using real medicine packages because of logistic and economic reasons, including the fact that many blisters or other secondary packages are opaque. This situation compromised the visual inspection of the surface of the medicines without opening the package.
CONCLUSIONS
Medicine imprints were rarely described in the sampled PLs, which seems to suggest that they are not regularly used as anti-counterfeiting measures. Some typographical and linguistic features were found that may not favour the adequate legibility and readability of the identified imprints. The use of informatics linguistic tools may constitute an important step for the conception and validation of medicine imprints. Furthermore, regulation may need to be updated on this issue.
